SUGAPOL-PM
MRP: 780
Packaging: 10x10
Pack Type: tablet
Composition:
Glimepiride 2mg + Pioglitazone 15mg + Metformin 500mg (In SR)
Indication:
Type 2 diabetes not responding to single agents or dual therapy
Description:
This triple oral anti-diabetic combination is formulated for effective management of Type 2 Diabetes Mellitus in patients who require multiple mechanisms of action to achieve glycemic control.
Glimepiride (2mg): A sulfonylurea that stimulates pancreatic insulin secretion.
Pioglitazone (15mg): A thiazolidinedione that enhances insulin sensitivity in muscle and adipose tissue.
Metformin SR (500mg): A biguanide that reduces hepatic glucose output and improves peripheral glucose uptake with sustained release action for prolonged efficacy.
Together, they provide comprehensive glycemic regulation, targeting insulin resistance, secretion, and glucose production.
Tags:
- Provides multi-mechanism control of Type 2 Diabetes
- Reduces insulin resistance (Pioglitazone)
- Stimulates insulin production (Glimepiride)
- Controls hepatic glucose output (Metformin SR)
Usage Information
Dosage
Usual dose: 1 tablet once daily with meals Dose may be adjusted by physician based on blood sugar levels Take at the same time each day for best effect
Side Effects
Hypoglycemia (especially if meals are skipped) Weight gain (possible with Pioglitazone) GI discomfort (Metformin-related) Edema or swelling Rare: Liver enzyme elevation, lactic acidosis
Contraindications
Type 1 Diabetes Heart failure (moderate to severe) Liver dysfunction Renal impairment History of bladder cancer (Pioglitazone caution) Hypersensitivity to any component
Availability
Glimepiride Pioglitazone Metformin tablet Triple anti-diabetic combination Type 2 diabetes medicine Metformin SR with Pioglitazone and Glimepiride Blood sugar control tablets